Synonyms: AEGR-733 | BMS-201038 | Juxtapid® | Lojuxta®
lomitapide is an approved drug (FDA (2012), EMA (2013))
Compound class:
Synthetic organic
Comment: Lomitapide is a lipid-lowering agent for the treatment of familial hypercholesterolemia.
View more information in the IUPHAR Pharmacology Education Project: lomitapide |
|
No information available. |
Summary of Clinical Use |
Approved to lower total cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Clinical formulations contain lomitapide mesylate (PubChem CID 11274333). |
Mechanism Of Action and Pharmacodynamic Effects |
Mechanistically lomatipide inhibits microsomal triglyceride transfer protein (MTTP, P55157). MTTP is required for the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces in the endoplasmic reticulum and this activity is required for the synthesis of apolipoprotein B (apo B). Lomatipide-induced reduction of apoB reduces VLDL and chylomicron formation and thus reduces LDL-cholesterol levels. Note that the microsomal triglyceride transfer protein is a heterodimer, composed of MTTP and protein disulfide isomerase (PDI, of which there are many isoforms). |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |